Loading...
•
Dec 31, 2023
Janux Q4 2023 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2023.
Key Takeaways
Janux Therapeutics reported a net loss of $11.8 million for the quarter and cash, cash equivalents, and short-term investments of $344.0 million as of December 31, 2023.
Presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC and for EGFR-TRACTr JANX008 in solid tumors.
Enrollment is ongoing for JANX007 and JANX008.
An update on JANX007 data and doses selected for expansion cohorts is anticipated in 2H 2024.
The company had $344.0 million in year-end cash, cash equivalents, and short-term investments.
Revenue by Segment
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...